Dear Helen

Many thanks for sending us NICE's updated estimates last week and for the opportunity to respond to these. After we had sent in our response on Friday last week, we received updated estimates for the number of NSCLC patients with advanced, non-squamous NSCLC and PS 2, receiving first-line chemotherapy in 2012, which is our starting population to calculate the number of patients eligible for pemetrexed second-line treatment.
We had requested these estimates to ensure that patient numbers for both the NSCLC and mesothelioma indications were based on 2012 data.

Data from the NLCA 2011 cohort had showed that there were a total of N=1,762 patients with non-squamous stage IIIB/IV NSCLC with PS 2 (*Personal communication,* [redacted] *2013*), of which, N=462 received any first-line treatment. The updated figures from 2012 (*Personal communication,* [redacted]*, on behalf of the NLCA project team, January 2014*) indicate that there are a total of N=1,400 patients with non-squamous stage IIIB/IV NSCLC with PS 2, of which N=429 received any first-line treatment.

As a result of this change, the estimated number of PS 2 patients eligible for pemetrexed second-line treatment changes from N=194 (as stated in our response to the third NICE ACD, dated December 18th 2013) to N=180. As a result of this change, the updated maximum plausible estimate for pemetrexed across all indications is N=6,789, rather than the figure of N=6,803 stated in our response dated 10th January 2014.

In the interest of consistency, we thought it was important to make the NICE technical team aware of these updated figures. Apologies for the delay in sending these.

Best regards
[redacted]

[redacted]

Tel: [redacted] Mobile: [redacted]
Fax: [redacted]

Answers That Matter.

CONFIDENTIALITY NOTICE: This e-mail message from Lilly UK (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. E-mail is susceptible to data corruption, interception, unauthorized amendment, tampering and viruses, and we only send and receive e-mails on the basis that we are not liable for any such corruption, interception, amendment, tampering or viruses or any consequences thereof.

Eli Lilly and Company Limited, a company incorporated in England under company registration number 284 385 and having its registered office at Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL